Pfizer
The Hundred-Billion-Dollar Pill: Inside Pfizer’s High-Stakes Gamble to Conquer the Weight-Loss Market
Pfizer is betting billions on an oral weight-loss pill to challenge Novo Nordisk and Eli Lilly’s injectable dominance in a market poised to hit $100B.
Pfizer’s $10 Billion Gambit: Winning the War for Metsera and the Future of Weight Loss
Pfizer outmaneuvered rival Novo Nordisk in a $10bn bidding war for weight-loss startup Metsera, a strategic move to combat its looming patent cliff.
Pharma’s High-Stakes Gamble: Inside the Pfizer vs. Novo Bidding War for a Weight-Loss Unicorn
A fierce bidding war erupts between Pfizer and Novo Nordisk for biotech firm Metsera, signaling a high-stakes battle for the future of the obesity drug market.
Pfizer’s $100 Billion Gamble: Inside the High-Stakes Battle for the Weight-Loss Drug Crown
Pfizer is playing hardball in the $100B weight-loss drug market, betting its future on a pill to challenge the injectable giants, Novo Nordisk and Eli Lilly.
The Washington Gauntlet: Why Every Megadeal Now Runs Through the White House
The world of M&A has been upended. Discover why Washington D.C. is the new gatekeeper for every megadeal and what it means for finance and investing.
High-Stakes Finance Unpacked: A PE Giant’s UK Nightmare, a Shadow Banking Mystery, and a Big Pharma Showdown
A deep dive into Cinven’s UK crisis, a fintech lending mystery involving a Utah bank, and Novo Nordisk’s strategic challenge to Pfizer.